FiercePharma  Apr 4  Comment 
Novartis, already in a legal battle to try to keep India's Wockhardt from launching a generic of its diabetes blockbuster Galvus, says it is now trying to prevent Biocon from doing the same thing.
The Straits Times  Apr 4  Comment 
April 04, 2014 11:27 PM NEW DELHI (AFP) - Leading Indian drug company Biocon on Friday rejected allegations by Novartis that it infringed on the Swiss pharmaceutical giant's patent for its blockbuster diabetes drug Galvus.     
Wall Street Journal  Apr 4  Comment 
Swiss drug giant Novartis installed new top management in Japan and put a freeze on clinical tests as it moves to restore its reputation after a string of questionable practices came to light about its clinical trials.
Reuters  Apr 3  Comment 
Novartis has taken Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday.
newratings.com  Apr 3  Comment 
Novartis data on 19 compounds at AACR highlight strong cancer pipeline across multiple molecular targets and biological pathways Novartis International AG / Novartis data on 19 compounds at AACR highlight strong cancer pipeline across multiple...
FiercePharma  Apr 2  Comment 
Novartis' Japanese unit didn't fake clinical data in a head-to-head leukemia drug study, an investigatory panel found. But that doesn't mean the Swiss drugmaker's staff is off the hook in its latest Japanese scandal. According to the panel's...
FierceBiotech  Apr 2  Comment 
The data aren't out yet, but the buzz about Novartis' new late-stage contender for blockbuster status is growing to fever pitch. This morning Leerink opted to add on $3 billion to the pharma giant's forecasted revenue for 2026, concluding that...
Forbes  Apr 1  Comment 
I try to avoid using words like "blockbuster" and "breakthrough" when writing about new drugs and treatments. I've been disappointed too many times. But, though they've been in short supply lately in cardiovascular medicine, sometimes there really...


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki